登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600715 证券简称：文投控股 编号：2026-001 文投控股股份有限公司 十一届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 文投控股股份有限公司（以下简称"公司"）十一届董事会第十一次会议于2026年1月27日9:30，以现场 结合通讯表决的方式召开。本次董事会会议为临时会议，由公司董事长徐建先生主持。本次会议应有9 名董事参会，实有9名董事参会（其中：董事施煜先生、独立董事杨步亭先生、独立董事安景文先生、 独立董事崔松鹤先生以通讯表决方式出席会议；董事何斐先生委托董事李玥女士出席会议并代为行使表 决权）。公司总经理、董事会秘书等高级管理人员列席会议。 本次会议的会议通知及会议材料已于2026年1月19日以通讯方式发出。本次会议的召集、召开、表决程 序符合《中华人民共和国公司法》《文投控股股份有限公司章程》《文投控股股份有限公司董事会议事 规则》及相关法律法规的规定，会议决议合法、有效。 表决结果：同意9票 ...

Core Viewpoint - The company reported a significant increase in revenue for the first three quarters of 2025, driven by domestic insulin product sales and international market expansion. Financial Performance - For the first three quarters of 2025, the company's revenue reached 3.047 billion yuan, an increase of 802 million yuan, representing a year-on-year growth of 35.73% [6] - Domestic insulin product sales contributed 2.624 billion yuan, up 822 million yuan from the previous year, with volume and price increases contributing 492 million yuan and 330 million yuan respectively [6][7] - International sales revenue was 353 million yuan, a year-on-year increase of 110 million yuan, or 45.52%, attributed to the company's global strategy and partnerships, particularly in Brazil [6][8] Non-Recurring Gains and Losses - The report indicates that there were non-recurring gains and losses, but specific details on amounts and classifications were not provided [4] Shareholder Information - The company will hold its first extraordinary general meeting of 2025 on November 17, 2025, with both onsite and online voting options available for shareholders [14][15] Governance Changes - The company plans to cancel its supervisory board and amend its articles of association, with the audit committee taking over the supervisory responsibilities [53][54] - The company has proposed updates to its operational scope, including new business areas such as rubber products and medical packaging [55]